All News

A conversation with Todd Bertoch, MD, chief medical officer for pain research at CenExel and an investigator on the ALLEVIATE-2 trial.

Ensitrelvir demonstrated a 67% relative risk reduction of developing symptomatic COVID-19 in household contact patients.

Deucravacitinib (Sotyktu) also demonstrates improvements in signs and symptoms, extra-articular manifestations, and patient-reported outcomes.

Patients aged 12 to under 18 saw clinically meaningful regrowth on the scalp, eyebrow, and eyelashes with both high-dose and low-dose treatment.

Representatives from Cencora’s Good Neighbor Pharmacy Network discussed legislation created to improve declining pharmacy rates and who is accountable for addressing pharmacy deserts.

Approximately 89.7% of patients taking CagriSema achieve the coprimary end point of weight loss of 5% or more compared with 30.3% on the placebo.

Researchers analyzed historical characteristics of bleeding disorders among women by highlighting clinical challenges and management strategies.

Investigators note that low itch and mild disease severity are maintained following a treatment-free interval of 80 days.

Researchers investigated the health benefits, utilization, harms, and costs associated with the use of alternative methods for colorectal cancer screening in Australia.

A conversation with Chelsee Jensen, PharmD, BCPS, director of formulary management at the Mayo Clinic.

COVID-19 vaccination before a SARS-CoV-2 infection was associated with a 75% reduced likelihood of long COVID symptoms that impact daily functioning among patients between the ages of 5 and 17 years.

Non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol levels could potentially be a valuable biomarker for determining the risk of diabetic kidney disease.

IQVIA released a report detailing pharmacists’ authority to administer vaccines in the US as well as adults’ overall vaccination rates by state.

In a previous study, results showed that patients taking semaglutide could be at a higher risk of nonarteritic anterior ischemic optic neuropathy (NAION), causing blindness.

Jennifer Zilka and Kyle Pudenz, DBA, introduced the issue of pharmacy deserts and discussed what has been driving store closures across the US.

The prevalence of depression and anxiety were also higher among younger patients and those who had a longer duration of pain.

Among postmenopausal women, researchers explored associations between intentional weight loss and waist circumference (WC) reduction and mortality.

The event will focus on clinical practice expansion for community pharmacies and how to make them a revenue-generating health care destination.

Coalition for Epidemic Preparedness Innovations experts warned of the potential for bird flu to become a pandemic event if officials don’t prepare quickly.

The ADjoin long-term extensive study is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis.

Omalizumab-igec is approved to treat moderate to severe persistent asthma in patients 6 years and older whose symptoms are not well controlled with inhaled corticosteroids.

Don Roosan, PharmD, PhD, discussed the artificial intelligence of ChatGPT and how it is currently being used in clinical pharmacy practices.

Investigators report that the safety profile is also similar between both drugs.

Join Shawn Bjorndal, PharmD, RPh, and Jesse McCullough, PharmD, for the first episode of Dispensing Leadership, a new podcast from Drug Topics® and RPhAlly.

After adjusting for confounding factors, women who experienced premature menopause had an increased risk of T2D.

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, discussed her experience when beginning to counsel patients using GLP-1 medications.

The feasibility study shows that the STEADY intervention is possible for patients with type 1 diabetes and eating disorders without deteriorating glycemic control.

Clinical pharmacists were asked to provide interventions to improve their patients’ rate of not showing up to a pharmacy appointment.

Cebranopadol met its primary endpoint of reduction in pain intensity as measured by the Pain Numeric Rating Scale (NRS) area under the curve from 2 through 48 hours.

The Cut Hypertension Program operates in barbershops across the Bay Area in California. The program’s lead pharmacist joined us to discuss main themes and goals of the new initiative.